Vivione Biosciences Inc. launches PC Bio energy solution at Unconventional Resources & Technologies (URTeC) 2014 conference
DALLAS--(BUSINESS WIRE)--Vivione Biosciences Inc. (“Vivione”) (TSXV:VBI), through its wholly owned subsidiary, Vivione Biosciences, LLC, launched its Petro Chemical Bio-Diagnostics (“PC Bio”) bacterial identification and enumeration solution this past week at the Unconventional Resources & Technologies (URTeC) 2014 conference held in Denver, Colorado.
“We were very pleased with the industry’s response at the show to our new offering. Our booth was very busy and the demonstrations held in our hospitality suite were well attended, leading to more than a dozen requests for specific sample testing as well as multiple requests for follow-up meetings.”
PC Bio is a strategic alliance between Vivione and the Institute for Environmental Health, Inc. (“IEH”) that offers a bio-diagnostics solution that quickly identifies and quantifies bacterial contamination levels in multiple oil & gas environments. It currently offers the oil & gas industry three critical solutions: 1) a characterization test which allows companies to identify and enumerate each bacteria species from sample wells, fields and/or other locations; 2) a bio-treatment efficacy test which allows companies to determine the effectiveness of a given treatment of a sample by measuring changes of bacterial activity pre- and post-treatment, and 3) periodic monitoring of changes in bacterial activity of a given environment so that remedial actions can be taken in a timely manner with greater precision. These services can be performed individually or as part of an ongoing “wellness” plan for a field or individual well.
“Given our experience setting new standards for rapid identification of bacteria and pathogens in food safety and clinical applications, we knew that we could provide the oil & gas industry with a rapid solution that positively impacts the decision making process, usually extending equipment life, reducing downtime and yielding higher well production” said Vivione’s Chief Executive Officer, Kevin Kuykendall. “We were very pleased with the industry’s response at the show to our new offering. Our booth was very busy and the demonstrations held in our hospitality suite were well attended, leading to more than a dozen requests for specific sample testing as well as multiple requests for follow-up meetings.”
Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.
Founded in 2001, IEH Laboratories & Consulting Group based in Seattle, Washington combines consulting with accredited testing laboratories to provide services in food, pharmaceutical and environmental safety. Routine testing and project study services are offered through the IEH network of laboratories with more than 119 national and international locations, backed by the expertise of more than 65 Ph.D. level IEH staff covering a wide range of disciplines. For more information, visit www.iehinc.com.
This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B system and the success of the PC Bio solution, Vivione’s business and growth strategy and the commercialization and the development of the Molecular Design technology. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.